NCT05139225View on ClinicalTrials.gov

A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

TTI-622

"(-2) 0.4 mg/kg (-1) 0.8 mg/kg~(1 ) 1.2 mg/kg (2) 2 mg/kg (3) 4 mg/kg (4) 8 mg/kg (5) 12 mg/kg~The appropriate dose of TTI-622 will be administered IV over 60 minutes, however, can be extended up to 4 hours to mitigate Infusion-related reactions."

DRUG

Daratumumab Hyaluronidase-fihj

Daratumumab hyaluronidase-fihj SC 1800 mg days 1, 8, 15, and 22.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Cancer Center, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
collaborator

Trillium Therapeutics Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER